Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized CMV-specific cytotoxic T-lymphocyte adoptive transfer after stem cell transplant
ISRCTN53325562Phase 2Completed
- Sponsor
- Kuur Therapeutics
- Start
- Oct 2010
- Modality
- Adoptive Cell Transfer → Cell Therapies
01
Overview
Phase 2, randomised, open-label trial of cytomegalovirus-specific cytotoxic t lymphocytes in cytomegalovirus disease (CMV) (2 arms), sponsored by Kuur Therapeutics. Primary endpoint: Frequency of CMV reactivation. Started Oct 2010; status: completed.
02
Drugs
cytomegalovirus-specific cytotoxic t lymphocytes
03
Conditions
cytomegalovirus disease (CMV)
Beyond the preview
Go deeper on ISRCTN53325562.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN53325562.